AEHR director Laura Oliphant sells company stock
AEHR TEST SYSTEMS director Laura Oliphant reported multiple open-market sales of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
AEHR TEST SYSTEMS director Laura Oliphant reported multiple open-market sales of common stock. On January 22, 2026, she sold 3,100, 1,026, 180, 100, and 140 shares of AEHR common stock at prices ranging from $31.38 to $31.485 per share.
After these transactions, she beneficially owned 18,432 shares directly and 7,665 shares indirectly through a trust. The directly held amount includes shares subject to unvested restricted stock units.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 3,100 | $31.38 | $97K |
| Sale | Common Stock | 1,026 | $31.44 | $32K |
| Sale | Common Stock | 180 | $31.45 | $6K |
| Sale | Common Stock | 100 | $31.46 | $3K |
| Sale | Common Stock | 140 | $31.485 | $4K |
| Holding | Common Stock | -- | -- | -- |
Footnotes (1)
- F1. The amount reported includes shares subject to unvested restricted stock units.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Who is the insider trading AEHR stock in this Form 4 filing?
The filing reports transactions by Laura Oliphant, a director of AEHR TEST SYSTEMS (AEHR). She is not listed as an officer or a 10% owner.
Do Laura Oliphant’s reported AEHR holdings include restricted stock units?
Yes. A footnote states that the amount reported for her directly held AEHR common stock includes shares subject to unvested restricted stock units.
AI-generated analysis. How Rhea-AI works. Not financial advice.